Recombinant Human CMAH Protein，GST

The study of CMAH (cytidine monophosphate N-acetylneuraminic acid hydroxylase) recombinant proteins has gained considerable attention due to their potential applications in various fields, including biotechnology, medicine, and genetics. CMAH is an enzyme responsible for converting CMP-N-acetylneuraminic acid (CMP-Neu5Ac) into CMP-sialic acid (CMP-Neu5Gc), a significant step in glycan biosynthesis. Alterations in CMAH activity have implications for human health, particularly concerning immune responses and potential cancer progression. In humans, a mutation in the CMAH gene has rendered the synthesis of Neu5Gc non-functional, which raises questions about evolutionary adaptations and the role of sialic acids in cell signaling and pathogen recognition. The recombinant expression of CMAH can help clarify its functional mechanisms and the biochemical pathways involved in sialic acid metabolism. Furthermore, producing CMAH in a controlled environment allows researchers to explore its structural properties, enzymatic activity, and interactions with specific substrates. This knowledge could lead to innovative therapeutic strategies, such as designing vaccines or studying autoimmune diseases, where sialic acid modification plays a crucial role. Additionally, understanding CMAH's function and regulation could provide insights into evolutionary biology by examining the implications of the CMAH gene mutation in humans versus other mammals. As research progresses, the development of CMAH recombinant proteins will likely open new avenues for research into glycoprotein engineering, enhancing our understanding of complex biological processes and their impact on health and disease.